Kyverna Therapeutics — Third Quarter 2026 Earnings Summary

Kyverna Therapeutics has completed the submission of a rolling Biologics License Application to the FDA for miv-cel in stiff person syndrome, requesting priority review under its Regenerative Medicine Advanced Therapy designation. The company reports that miv-cel demonstrated durable efficacy and a well-tolerated safety profile in registrational trials, with no high-grade cytokine release syndrome or neurotoxicity observed. Financial results for the third quarter of 2026 show a net loss of $41.9 million, while the company maintains $170.6 million in cash and marketable securities to support operations into 2028. Additionally, enrollment for the Phase 3 gMG trial is on track for completion in mid-2027, and the KYV-102 program has been deprioritized to focus resources on late-stage neurologic indications.